Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Thrombocytopenia 4Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Hodgkin Disease 2Solid Tumor 1Sarcoma, Ewing 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Glioblastoma 1Chemotherapy-induced Thrombocytopenia 1

Interventions

Cyclophosphamide 165fludarabine phosphate 110Peripheral Blood Stem Cell Transplantation 94Mycophenolic Acid 88Whole-Body Irradiation 81Etoposide 81Tacrolimus 73Busulfan 68Melphalan 67Filgrastim 66fludarabine 62Radiotherapy 56Doxorubicin 54Cyclosporine 54Rituximab 50Brentuximab Vedotin 48Antilymphocyte Serum 47Granulocyte Colony-Stimulating Factor 42Vinblastine 41Methotrexate 38Dacarbazine 37Cytarabine 35Gemcitabine 34Nivolumab 30Bleomycin 29Carmustine 28Vincristine 25Prednisone 25Sirolimus 24Bendamustine Hydrochloride 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Hodgkin Disease × romiplostim × Clear all
NCT04478123 2024-02-14

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
62 enrolled 7 charts
Classical hematologyLymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Thrombocytopenia

NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡